BioPharma Compass 3.1 (BPC 3.1) is a wizard-driven, workflow-based software platform, suitable for mass spectrometry experts and routine users alike. Methods developed in a non-regulated environment can be locked down for routine biopharmaceutical analysis deployment. The customizable workspace adapts to the task at hand, including user interface, method development, and data review; all from the comfort of your office PC.
BPC 3.1 enables the routine of biopharmaceutical analysis offering dedicated LC and MS workflows from automated measurements to report generation. Such workflows are increasingly important in biopharmaceutical development, e.g., to verify protein sequences and to quantify product and process related heterogeneities such as modification profiles. These Multi-Attribute Methods (MAM) are implemented in BPC 3.1 to reduce report turnaround times and throughput using high resolution ESI-QTOF or MALDI-TOF mass spectrometry.
These MAM-assays can be carried out at the intact, domain (subunits) or peptide level using MS-only or MS/MS for top-down and bottom-up analysis. Dedicated similarity scoring enables automatic result assessment and reporting with color-coded results to accelerate data review. Butterfly plots enable visual dataset comparisons.
BPC 3.1 automates common biopharmaceutical analysis workflows from acquisition and analysis to full reports. Laboratories under 21 CFR Part 11 compliance will benefit from the regulatory options, including leading data security features.
The ultra-high resolution data from Bruker’s maXis II UHR QTOF are uniquely beneficial to the identification of low level protein isoforms, conjugates or glycoforms during mAb characterization. With Bruker's patented SNAP II algorithm and True Isotopic Pattern (TIP™) data quality, monoisotopic masses - e.g., of mAb subunits - are automatically assigned with sub-ppm accuracy. Scoring as element of the workflows provides automated quality assessment simplifying batch comparisons. Butterfly plots allow visual dataset comparison.
Bruker's market-leading MALDI-TOF/TOF and QTOF-ESI/ETD high resolution platforms provide rapid middle-down and middle-up protein biopharmaceutical analysis. The resulting data provide automatic sequence confirmation and support sequence curation, N/C-terminal status assessment (clipping variants) and localization of sequence variants, mis-incorporations and other quality attributes.
